The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Therapeutic targeting of PP2A
Open accessAbstract
Protein phosphatase 2A (PP2A) is a major serine/threonine phosphatase that regulates many cellular processes. Given the central role of PP2A in regulating diverse biological functions and its dysregulation in many diseases, including cancer, PP2A directed therapeutics have become of great interest. The main approaches leveraged thus far can be categorized as follows: 1) inhibiting endogenous inhibitors of PP2A, 2) targeted disruption of post translational modifications on PP2A subunits, or 3) direct targeting of PP2A. Additional insight into the structural, molecular, and biological framework driving the efficacy of these therapeutic strategies will provide a foundation for the refinement and development of novel and clinically tractable PP2A targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells.
Seamon, K. B., Padgett, W., & Daly, J. W. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.6.3363 · Cited by 1,658 · cited 4×
“…et al., 2015; Lv et al., 2014; Wei et al., 2013; Zhang et al., 2015) Other Targets Unknown Forskolin, Vitamin E analogs, Lanolinamide, Canthardin (Feschenko et al., 2002; Huang et al., 2009; Kar et al., 2012; Neuzil et al., 2002; Neviani et al., 2005a; Seamon et al., 1981) Int J Biochem Cell Biol.”
BackgroundInfluentialSerine/threonine phosphatases: mechanism through structure
Shi, Y. (2009) · Cell · doi:10.1016/j.cell.2009.10.006 · Cited by 1,488 · cited 3×
“The specificity of this unique type of terminal carboxyl methylation restricts LCMT-1 and PME-1 activity to the phosphoprotein phosphatase enzymes PP2A, PP4, and PP6, further highlighting their potential as selective therapeutic targets.”
BackgroundCappuzzo, F., Ciuleanu, T., Stelmakh, L., Cicenas, S., Szczésna, A., Juhász, E., Esteban, E., Molinier, O., Brugger, W., Melezínek, I., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70112-1 · Cited by 1,186 · cited 1×
“First, in a phase II all comers clinical trial, a small subset of EGFR wild-type patients also respond to Erlotinib treatment (Cappuzzo et al., 2010; Ciuleanu et al., 2012; Wang et al., 2014).”
BackgroundCIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677 · cited 15×
“CIP2A is a PP2A interacting protein that prevents PP2A mediated dephosphorylation of c-MYC at Ser 62 and AKT at Ser 473, resulting in the stabilization of c-MYC and increased AKT activity, respectively (Khanna et al., 2013; Sangodkar et al., 2015).”
BackgroundInfluentialLiang, J., Nagahashi, M., Kim, E. Y., Harikumar, K. B., Yamada, A., Huang, W.-C., Hait, N. C., Allegood, J. C., Price, M. M., Avni, D., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.013 · Cited by 563
Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme
Cho, U. S., & Xu, W. (2007) · Nature · doi:10.1038/nature05351 · Cited by 459 · cited 8×
“Crystal structure data of a B56γ containing heterotrimer demonstrated how the negatively charged carboxyl group of the non-methylated L309 prevented the C-terminal tail from interacting with the E64 residue of the scaffolding A subunit (Cho and Xu, 2007).”
BackgroundInfluentialStructure of the Protein Phosphatase 2A Holoenzyme
Xu, Y., Xing, Y., Chen, Y., Chao, Y., Lin, Z., Fan, E., Yu, J. W., Strack, S., Jeffrey, P. D., & Shi, Y. (2006) · Cell · doi:10.1016/j.cell.2006.11.033 · Cited by 450 · cited 2×
“Supportive of this, residues along this hydrophobic ridge serve as important contact points between subunits in the solved crystal structures (Cho and Xu, 2007; Groves et al., 1999; Wlodarchak et al., 2013; Xu et al., 2006).”
BackgroundGroves, M. R., Hanlon, N., Turowski, P., Hemmings, B. A., & Barford, D. (1999) · Cell · doi:10.1016/s0092-8674(00)80963-0 · Cited by 442 · cited 3×
“…at the Tyrosine 307 (Y307) residue and, 3) the unique methylation of a carboxy-terminal Leucine 309 (L309) residue (Evans et al., 1999; Groves et al., 1999; Guo et al., 2014; Jennifer B. Jackson and Pallas, 2012; Longin et al., 2007; Ortega-Gutirrez et al., 2008; Xing et al., 2008;…”
BackgroundProtein phosphatase 2A: a target for anticancer therapy
Perrotti, D., & Neviani, P. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70558-2 · Cited by 400 · cited 1×
“…at Y307 has been implicated as a marker of PP2A inactivation and thought to inversely correlate with disease prognosis in select hematologic malignancies and solid tumors (I Cristóbal et al., 2014; Farrell et al., 2015; Neviani et al., 2005a; Perrotti and Neviani, 2013; Rincón et al., 2015).”
BackgroundCiuleanu, T., Stelmakh, L., Cicenas, S., Miliauskas, S., Grigorescu, A. C., Hillenbach, C., Johannsdottir, H. K., Klughammer, B., & Gonzalez, E. E. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70385-0 · Cited by 374 · cited 1×
“First, in a phase II all comers clinical trial, a small subset of EGFR wild-type patients also respond to Erlotinib treatment (Cappuzzo et al., 2010; Ciuleanu et al., 2012; Wang et al., 2014).”
Background
Cited by
Therapeutic targeting of “undruggable” MYC
Llombart, V., & Mansour, M. R. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2021.103756 · Cited by 472
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells
Kauko, O., O’Connor, C. M., Kulesskiy, E., Sangodkar, J., Aakula, A., Izadmehr, S., Yetukuri, L., Yadav, B., Padzik, A., Laajala, T. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1093 · Cited by 149
“Finally, our screen conducted with 230 kinase inhibitors in PP2A-modulated cells provides a resource for further identification of combination therapy strategies, in particular with pharmacological PP2A modulators such as SMAPs (37).”
BackgroundSelf-citationNon-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer
Kauko, O., & Westermarck, J. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.01.005 · Cited by 111
Allen-Petersen, B. L., Risom, T., Feng, Z., Wang, Z., Jenny, Z. P., Thoma, M. C., Pelz, K. R., Morton, J. P., Sansom, O. J., Lopez, C. D., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-0717 · Cited by 85
Self-citationKauko, O., Imanishi, S. Y., Kulesskiy, E., Yetukuri, L., Laajala, T. D., Sharma, M., Pavic, K., Aakula, A., Rupp, C., Jumppanen, M., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011265 · Cited by 65
“In addition, these findings provide a knowledge resource for the development of combination strategies with the emerging PP2A-targeted therapies aiming either to reactivate (17, 18) or inhibit (62) PP2A (Fig.”
BackgroundPathogen protein modularity enables elaborate mimicry of a host phosphatase
Li, H., Wang, J., Kuan, T. A., Tang, B., Feng, L., Wang, J., Cheng, Z., Skłenar, J., Derbyshire, P., Hulin, M., et al. (2023) · Cell · doi:10.1016/j.cell.2023.05.049 · Cited by 53
Metadata
- Authors
- O’Connor, C. M., Perl, A., Leonard, D., Sangodkar, J., & Narla, G.
- Venue
- The International Journal of Biochemistry & Cell Biology
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 96
- Pages
- 182-193
- ISSN
- 1357-2725 (ISSN-L)
- OpenAlex
- W2767014526
- Cited by
- 190
- References
- 31
- FWCI
- 5.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.